Meeting
2018 Genitourinary Cancers Symposium
Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).
Authors
Megan Ann McNamara
Duke University Medical Center, Mornsville, NC
Megan Ann McNamara , Michala Ritz , Bennett Chin , Jorge Oldan , Aseem Anand , Taofik Oyekunle , Monika Anand , Andrew J. Armstrong , Daniel J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 222)
DOI
10.1200/JCO.2018.36.6_suppl.222
Abstract #
222
Poster Bd #
K20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters
Poster
2019 Genitourinary Cancers Symposium
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
First Author: Alastair Thomson
Poster
2017 Genitourinary Cancers Symposium
Evaluation of treatment patterns and costs for patients with prostate cancer and bone metastases.
First Author: Adriana Valdarrama